Balaxi Pharma Standalone March 2025 Net Sales at Rs 9.65 crore, down 39.33% Y-o-Y
Broker Research
June 24, 2025 / 11:23 IST
Reported Standalone quarterly numbers for Balaxi Pharmaceuticals are: Net Sales at Rs 9.65 crore in March 2025 down 39.33% from Rs. 15.90 crore in March 2024. Quarterly Net Loss at Rs. 1.18 crore in March 2025 down 104.89% from Rs. 0.58 crore in March 2024. EBITDA stands negative at Rs. 0.33 crore in March 2025 down 189.19% from Rs. 0.37 crore in March 2024. Balaxi Pharma shares closed at 49.76 on June 20, 2025 (NSE) and has given -32.32% returns over the last 6 months and -58.62% over the last 12 months.
| Balaxi Pharmaceuticals | | Standalone Quarterly Results | in Rs. Cr. |
|
Story continues below Advertisement
| Mar'25 | Dec'24 | Mar'24 | | Net Sales/Income from operations | 9.65 | 11.16 | 15.90 | | Other Operating Income | -- | -- | -- | | Total Income From Operations | 9.65 | 11.16 | 15.90 | | EXPENDITURE | | Consumption of Raw Materials | 8.22 | 9.31 | 13.46 | | Purchase of Traded Goods | -- | -- | -- | | Increase/Decrease in Stocks | -- | -- | -- | | Power & Fuel | -- | -- | -- | | Employees Cost | 1.34 | 1.19 | 0.60 | | Depreciation | 0.11 | 0.11 | 0.12 | | Excise Duty | -- | -- | -- | | Admin. And Selling Expenses | 0.74 | 0.56 | 1.64 | | R & D Expenses | -- | -- | -- | | Provisions And Contingencies | -- | -- | -- | | Exp. Capitalised | -- | -- | -- | | Other Expenses | -- | -- | -- | | P/L Before Other Inc. , Int., Excpt. Items & Tax | -0.77 | -0.02 | 0.08 | | Other Income | 0.32 | 2.92 | 0.16 | | P/L Before Int., Excpt. Items & Tax | -0.44 | 2.90 | 0.25 | | Interest | 0.69 | 0.57 | 0.51 | | P/L Before Exceptional Items & Tax | -1.14 | 2.33 | -0.26 | | Exceptional Items | -- | -- | -- | | P/L Before Tax | -1.14 | 2.33 | -0.26 | | Tax | 0.04 | 0.59 | 0.31 | | P/L After Tax from Ordinary Activities | -1.18 | 1.74 | -0.58 | | Prior Year Adjustments | -- | -- | -- | | Extra Ordinary Items | -- | -- | -- | | Net Profit/(Loss) For the Period | -1.18 | 1.74 | -0.58 | | Equity Share Capital | 11.04 | 11.04 | 10.90 | | Reserves Excluding Revaluation Reserves | -- | -- | -- | | Equity Dividend Rate (%) | -- | -- | -- | | EPS Before Extra Ordinary | | Basic EPS | -0.21 | 0.32 | -0.55 | | Diluted EPS | -0.21 | 0.32 | -0.55 | | EPS After Extra Ordinary | | Basic EPS | -0.21 | 0.32 | -0.55 | | Diluted EPS | -0.21 | 0.32 | -0.55 | | Public Share Holding | | No Of Shares (Crores) | -- | -- | -- | | Share Holding (%) | -- | -- | -- | | Promoters and Promoter Group Shareholding | | a) Pledged/Encumbered | | - Number of shares (Crores) | -- | -- | -- | | - Per. of shares (as a % of the total sh. of prom. and promoter group) | -- | -- | -- | | - Per. of shares (as a % of the total Share Cap. of the company) | -- | -- | -- | | b) Non-encumbered | | - Number of shares (Crores) | -- | -- | -- | | - Per. of shares (as a % of the total sh. of prom. and promoter group) | -- | -- | -- | | - Per. of shares (as a % of the total Share Cap. of the company) | -- | -- | -- | | Source : Dion Global Solutions Limited |
|
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
